How is it December already? In the retail world, the holiday season seems to begin earlier every year. It felt like ads for Thanksgiving and Christmas started airing around Labor Day this year here in the United States. Last year, I noticed my thoughts turned to my donor family more…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an investigational oral medicine for idiopathic pulmonary fibrosis (IPF). This designation gives Algernon Pharmaceuticals, as the therapy’s developer, certain incentives including tax credits, fee waivers, and a guarantee for…
The first-of-its-kind Vicore COMPANION Study is now recruiting participants across the U.S. to test Almee, a new artificial intelligence (AI) app designed to help people with pulmonary fibrosis (PF) manage their anxiety. Developed by Vicore Pharma, Almee is an investigational digital cognitive behavioral therapy (CBT) that uses…
Life is full of important reflections. As a child and teenager, I moved at lightning speed, never wanting to miss out on an opportunity. Since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I’ve been forced to slow down, as my declining lungs no longer allow…
The holiday season is upon us! Here in the United States, Thanksgiving was last week, and the Macy’s Thanksgiving Day Parade heralded the arrival of Santa Claus. But November, for the past two years, has been a month of loss for me. COVID-19 and transplant In March 2020, the reality…
Kinarus Therapeutics and the Great Health Companion Group (GHCG) in China are exploring a partnership to fund further development of KIN001, Kinarus’ potential treatment for idiopathic pulmonary fibrosis (IPF). Switzerland-based Kinarus and GHCG, a subsidiary of global China conglomerate Hakim Unique Group, are also looking into ways to…
Being diagnosed with a chronic illness changes everything. In addition to the physical changes, patients endure emotional, mental, and social ones as well. This is especially true for those of us thrown into the chronic illness world as a young adult, when our brains have just finished developing but our…
The pulmonary fibrosis (PF) patient population would likely become unhinged without the oversight of our caregivers. They have one of the hardest roles in the PF community. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, my wife, Susan, was sitting by my side. For…
TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or fibrosis, in the lungs of a rat model of the disease. Its effectiveness was comparable to that of the approved IPF therapy, Ofev (nintedanib) and was consistent with findings…
PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…
Get regular updates to your inbox.
